Bellevue Group AG Invests $457,000 in Denali Therapeutics Inc. (NASDAQ:DNLI)

Bellevue Group AG purchased a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 15,700 shares of the company’s stock, valued at approximately $457,000.

Other hedge funds also recently added to or reduced their stakes in the company. MONECO Advisors LLC boosted its holdings in shares of Denali Therapeutics by 4.6% in the 3rd quarter. MONECO Advisors LLC now owns 9,100 shares of the company’s stock valued at $265,000 after buying an additional 400 shares in the last quarter. Assetmark Inc. boosted its stake in Denali Therapeutics by 18.0% in the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock valued at $111,000 after acquiring an additional 580 shares in the last quarter. CWM LLC grew its holdings in shares of Denali Therapeutics by 43.6% during the third quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after purchasing an additional 654 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Denali Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after purchasing an additional 920 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Denali Therapeutics by 5.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,403 shares of the company’s stock valued at $613,000 after purchasing an additional 1,372 shares during the last quarter. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on DNLI. JPMorgan Chase & Co. dropped their price target on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Cantor Fitzgerald cut shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 7th. HC Wainwright reiterated a “buy” rating and set a $90.00 price target on shares of Denali Therapeutics in a research note on Thursday, November 7th. Bank of America lifted their price objective on shares of Denali Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Finally, Jefferies Financial Group increased their target price on shares of Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $38.90.

Insider Buying and Selling at Denali Therapeutics

In related news, Director Vicki L. Sato sold 1,020 shares of the firm’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $30.00, for a total value of $30,600.00. Following the completion of the sale, the director now owns 111,056 shares in the company, valued at $3,331,680. This trade represents a 0.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Alexander O. Schuth sold 15,558 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $29.91, for a total transaction of $465,339.78. Following the sale, the insider now directly owns 178,066 shares in the company, valued at approximately $5,325,954.06. This represents a 8.04 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 86,578 shares of company stock valued at $2,474,440. 7.90% of the stock is owned by company insiders.

Denali Therapeutics Stock Down 0.6 %

Shares of NASDAQ:DNLI opened at $25.00 on Monday. Denali Therapeutics Inc. has a 52 week low of $14.56 and a 52 week high of $33.33. The company has a 50-day moving average price of $27.29 and a 200 day moving average price of $24.53. The company has a market cap of $3.60 billion, a P/E ratio of -9.06 and a beta of 1.40.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter last year, the business earned ($0.72) earnings per share. Analysts expect that Denali Therapeutics Inc. will post -2.69 EPS for the current year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.